Genprex (GNPX) announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company’s diabetes gene therapy drug candidate, at the 2025 American Diabetes Association, ADA, 85th Scientific Session in Chicago. These studies used an alternative second-generation approach with a non-viral lipid nanoparticle delivery system. This exploratory research represents the Company’s forward-thinking work within its diabetes program to determine if the novel diabetes gene therapy can be delivered using a non-viral delivery system which could allow for repeat dosing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX:
- Genprex Enters $12.5M Stock Purchase Agreement
- Genprex files to sell 15M shares of common stock for holders
- Genprex collaborators present positive preclinical data of GPX-002 in diabetes
- Genprex files to sell 27.59M shares of common stock, prefunded warrants
- Genprex Announces Research Agreement for Diabetes Therapy